Publications dans lesquelles il/elle collabore avec Eduardo Ansorena Artieda (19)

2023

  1. Structure, regulation, and physiological functions of NADPH oxidase 5 (NOX5)

    Journal of Physiology and Biochemistry, Vol. 79, Núm. 2, pp. 383-395

2022

  1. Endothelial NOX5 expression modulates thermogenesis and lipolysis in mice fed with a high-fat diet and 3T3-L1 adipocytes through an interleukin-6 dependent mechanism

    Antioxidants, Vol. 11, Núm. 1

2021

  1. Endothelial nox5 expression modulates glucose uptake and lipid accumulation in mice fed a high-fat diet and 3t3-l1 adipocytes treated with glucose and palmitic acid

    International Journal of Molecular Sciences, Vol. 22, Núm. 5, pp. 1-17

  2. Optimization of a GDNF production method based on Semliki Forest virus vector

    European Journal of Pharmaceutical Sciences, Vol. 159

2016

  1. Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys

    Biomaterials, Vol. 110, pp. 11-23

2014

  1. Vascular endothelial growth factor-loaded injectable hydrogel enhances plasticity in the injured spinal cord

    Journal of Biomedical Materials Research - Part A, Vol. 102, Núm. 7, pp. 2345-2355

2013

  1. A simple and efficient method for the production of human glycosylated glial cell line-derived neurotrophic factor using a Semliki Forest virus expression system

    International Journal of Pharmaceutics, Vol. 440, Núm. 1, pp. 19-26

  2. Drug development in Parkinson's disease: From emerging molecules to innovative drug delivery systems

    Maturitas, Vol. 76, Núm. 3, pp. 272-278

  3. Injectable alginate hydrogel loaded with GDNF promotes functional recovery in a hemisection model of spinal cord injury

    International Journal of Pharmaceutics, Vol. 455, Núm. 1-2, pp. 148-158

2012

  1. Brain drug delivery systems for neurodegenerative disorders

    Current Pharmaceutical Biotechnology, Vol. 13, Núm. 12, pp. 2388-2402

2011

  1. Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease

    Movement Disorders, Vol. 26, Núm. 10, pp. 1943-1947

2010

  1. Production of highly pure human glycosylated GDNF in a mammalian cell line

    International Journal of Pharmaceutics, Vol. 385, Núm. 1-2, pp. 6-11

2009

  1. Effective GDNF brain delivery using microspheres-A promising strategy for Parkinson's disease

    Journal of Controlled Release, Vol. 135, Núm. 2, pp. 119-126

  2. Nanosistemas a base de poliésteres

    Nanotecnología farmacéutica: realidades y posibilidades farmacoterapéuticas (Real Academia Nacional de Farmacia), pp. 41-101

2008

  1. Controlled drug delivery to the brain: an overview

    Handbook of particulate drug delivery (American Scientific Publishers), pp. 121 - 142

  2. Sustained release of bioactive glycosylated glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 69, Núm. 3, pp. 844-851

2007

  1. Microencapsulación de factores neurotróficos: Aplicación al tratamiento de la enfermedad de Parkinson

    Mapfre Medicina, Vol. 18, Núm. 4, pp. 240-248

  2. Purification of bioactive glycosylated recombinant glial cell line-derived neurotrophic factor

    International Journal of Pharmaceutics, Vol. 344, Núm. 1-2, pp. 9-15

2006

  1. Terapias neuroprotectoras y neurorestauradoras en el tratamiento de la enfermedad de Parkinson

    Anales del sistema sanitario de Navarra, Vol. 29, Núm. 3, pp. 325-335